ISDA

Entry Detail

PDB ID:

7TZ0

EMDB ID:

EMD-26201

Keywords:

VIRAL PROTEIN/ANTIVIRAL PROTEIN

Title:

Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin (Local refinement of FSR22 and RBD)

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2, Escherichia phage EcSzw-2Escherichia coli

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2022-02-15

Release Date:

2022-12-07

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

4.17 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Mutations:F817P, A892P, A899P, A942P, K986P, V987P
Chain IDs:A
Chain Length:1247
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF16451, PF09408, PF19209, PF01601

Polymer Type:polypeptide(L)
Description:DARPin FSR22
Chain IDs:B
Chain Length:225
Number of Molecules:1
Biological Source:Escherichia phage EcSzw-2Escherichia coli

Ligand Molecules

Primary Citation

A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins.

Chonira, V, Kwon, Y.D, Gorman, J, Case, J.B, Ku, Z, Simeon, R, Casner, R.G, Harris, D.R, Olia, A.S, Stephens, T, Shapiro, L, Bender, M.F, Boyd, H, Teng, I.T, Tsybovsky, Y, Krammer, F, Zhang, N, Diamond, M.S, Kwong, P.D, An, Z, Chen, Z.Show

Nat.Chem.Biol. 19 284 291 (2023)

PMID: 36411391 DOI: 10.1038/s41589-022-01193-2

Abstact

We report the engineering and selection of two synthetic proteins-FSR16m and FSR22-for the possible treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. FSR16m and FSR22 are trimeric proteins composed of DARPin SR16m or SR22 fused with a T4 foldon. Despite selection by a spike protein from a now historical SARS-CoV-2 strain, FSR16m and FSR22 exhibit broad-spectrum neutralization of SARS-CoV-2 strains, inhibiting authentic B.1.351, B.1.617.2 and BA.1.1 viruses, with respective IC50 values of 3.4, 2.2 and 7.4 ng ml-1 for FSR16m. Cryo-EM structures revealed that these DARPins recognize a region of the receptor-binding domain (residues 456, 475, 486, 487 and 489) overlapping a critical portion of the angiotensin-converting enzyme 2 (ACE2)-binding surface. K18-hACE2 transgenic mice inoculated with B.1.617.2 and receiving intranasally administered FSR16m showed less weight loss and 10-100-fold lower viral burden in upper and lower respiratory tracts. The strong and broad neutralization potency makes FSR16m and FSR22 promising candidates for the prevention and treatment of infection by SARS-CoV-2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures